The medical industry is full of gold in-body diagnosis has a "money" scene

The medical industry is full of gold, and in vitro diagnostics (IVD) is the most "money" industry of 2016. In 2015, China's in-body diagnostics market was 50 billion yuan, with an overall growth rate of 17%, and is expected to maintain a growth rate of 15-20% in the next 3-5 years.
in the next 5-10 years, the IVD market growth rate in developing countries will be the fastest, and China, as one of the "BRIC" emerging markets, has become a target for stags, but also for domestic companies to bring a broad space for development.the larger the hospital inspection department, the smaller the voice
in-body diagnosis in the hospital income ratio distribution, we can see that the test department is up to 7.5-12%, which is a general hospital.
if it were a specialist hospital, it could be 30-40 per cent. Why is it so high? Because other departments earn less.IvD is distributed in hospitals
so the larger the hospital ratio, the lower the proportion of smaller hospitals. The larger the hospital inspection department director's voice is also smaller, while the other clinical hospital director's voice is relatively high, because they will send a lot of testing items in the inspection department's income, now the obstetrics and gynecology is more serious, because there are many items of prenatal screening combined costs also have 34,000 yuan.
bio-chemicals department can see that the proportion of departments 33-40%, costs as a proportion of income 18-22%, immunization departments accounted for 20-35% of the proportion of departments.
: In-body diagnostics are the biggest growth driver in China's medical device market in the future.
Insotrofic diagnosis in China's hospitals accounted for more than 10% of the income, and the profit share has exceeded
30%;
the state strictly control the proportion of drugs, cancel the purchase of drugs to increase the price (will also eliminate the purchase of high-value supplies to increase the price) and other medical reform measures will further increase the hospital's dependence on in-body diagnostic products
IVD market opportunities under the hierarchical diagnosis and treatment
under the acceleration of national medical reform, the main opportunities for future IVD enterprises are: primary medical institutions, clinical departments of large hospitals.
Market Opportunities - Bio-Chemical
Traditional Clinical Bio-Reagents for the following reasons:
There are 25 bio-chemical reagent companies in Shaoxing, Zhejiang Province alone, and the number of bio-chemical reagent companies in China as a whole is still a mystery. This year, the government will strengthen supervision (GMP plant, registration fee system, strict investigation of clinical results fraud, flight inspection, etc.), will promote industry integration.
foreign companies (Roche, Beckman, Abbott, etc.) and industry-leading domestic companies (Nine, Lidman, Mike, Meekon, Murray, etc.) will work together to close the door on a number of small manufacturers.
treatment, the number of difficult cases and critical cases in Sanjia Hospital will gradually increase, which is good for foreign brands with excellent performance. Hospitals below the third level will be occupied by leading domestic companies.
Market Opportunities - Immunity
Small Desktop Instruments or POCT (Microflow Control) for the following reasons:
drugs are long-term depressed objects, economic interests prompt the clinical departments of level 3 hospitals to set up their own laboratories, simple operation, small footprint of the instrument will be favored, but the results accurate must be the first element of clinical department selection.
treatment, patients will sink to primary health care institutions, the demand for small automated bench-based equipment or POCT will explode and increase, easy to operate, equipment, low cost of supplies is the first element chosen by primary medical institutions.
microflow control is the only POCT platform that can match large instruments in accuracy and repeatability, and projects can be light-emitting immunity and molecular diagnostics.Immune new technology
liquid phase chip is essentially a chemical luminescence and flow cytometer
on different fluorescent-encoded microspheres on antigen-antibodies, enzyme-substrates, lien-receptor binding reactions and nucleic acid hybridization reactions, through a single beam or multi-beam laser to detect microsphere coding and fluorescence intensity to achieve qualitative and quantitative purposes.
are currently encoded in a variety of ways, such as the color of the microball, the volume of the microball, the scratches of the microball and so on. Among them, the U.S. Luminix instrument is the first FDA-certified biochip technology for clinical diagnosis.
Market Opportunities - Molecular Diagnostics
PCR amplification based on the combination of pathogens in emergency departments and primary medical institutions
multiple citations, while detecting a variety of microorganisms of the same disease (viruses, bacteria, fungi, mycoids, etc.), more common are respiratory microbiological syndrome, digestive microbial syndrome, acute blood infection bacteria population, etc.
The fully automated system of individualized drugs based on genetic testing
tumor individualized medical treatment (gene mutation point detection, e.g. EGFR, KARS, etc.), other diseases (bacterial drug-resistant genes, clopidogrel CYP2C19, allopurinol HLA-B-5801, folic acid MTHFRC677T, etc.).
new technology for molecular diagnostics
Cehpeid's Modular Automatic PCR
Target Market: Bacterial Drug-Resistant Gene Detection (MRSA, TB, etc.)
Methodology: Integrated DNA Extraction and PCR Amplification
Machine Design: Single Modular Design, Easy combination Similar Manufacturers
Biofire: Acquired by Merrier and expected to enter the Chinese market by the end of the year
Gentuna: A domestic enterprise agent
molecular diagnostic new technology 2
Merier's fully automated multi-project pathogen detection
target market: outpatient or clinical department.
methodology: PCR amplification of multiple pronirtics, while detecting a variety of microorganisms (viruses, bacteria, fungi, myganisms, etc.) of the same disease.
machine design: front end (DNA extraction, purification) and back end are PCR microflow control chips. similar manufacturers
only Beijing Bo wei innovation (instruments developed by foreign teams), the project for HPV parting testing. (Cypress Blue Equipment)